# Genbioma Aplicaciones, S.L.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genbioma-aplicaciones-s-l

- Industry: Pharmaceuticals
- Headquarters: Spain
- Website: www.genbioma.com
- Total disclosed funding: $0.5M
- Latest round: Seed (Jan 26, 2021)
- Investors on record: 1

## About

Genbioma Aplicaciones, S.L. is a Spanish company focused on developing innovative probiotic and bioactive solutions. Their products aim to enhance health through scientifically validated ingredients.Founded in 2019 and headquartered in Spain, Genbioma Aplicaciones, S.L. specializes in the research and development of probiotics and bioactive compounds. The company raised EUR 0.4 million in Seed funding led by Clave Capital in January 2021, marking a significant milestone in their funding journey. The founder, whose details are currently unspecified, has established a singular focus on advancing the science of microbiome health.Genbioma Aplicaciones S.L. specializes in the research and development of innovative, science-based solutions in the field of probiotics and other bioactive compounds. Their core product offerings include probiotic and postbiotic supplements that are backed by extensive scientific research and trials. Among their notable products are the pA1c(R) and Reglubetic(R) strains, designed for daily oral supplementation to support health through microbiome science. These supplements are crafted for the dietary supplement and food industries, targeting businesses that require evidence-based ingredients to enhance their product lines. Genbioma's products are primarily marketed to partners in various international markets, with a focus on sectors that demand high-quality, scientifically validated probiotic solutions.Genbioma operates as a B2B provider, engaging with clients in the dietary supplement and food industries through partnerships and collaborations. The company’s revenue model is structured around supplying innovative probiotic and postbiotic ingredients to business clients, who may incorporate these into their own products. Transactions typically involve bulk orders of their flagship products, such as pA1c(R) and Reglubetic(R), where clients benefit from customized formulations designed to meet specific health needs. The partnership approach enables Genbioma to foster long-term relationships with its clients, ensuring a stable revenue stream derived from ongoing collaborations and continuous product development in the probiotic sector.Genbioma Aplicaciones, S.L. plans to leverage the EUR 0.4 million raised in Seed funding to enhance its product development efforts, particularly in launching new probiotic formulations targeted for the dietary supplement market. The company is focusing on expanding its presence into new international markets, with specific attention to regions in Europe and North America by 2023. These initiatives are designed to broaden their reach and capitalize on the growing demand for scientifically validated probiotic solutions.

## Funding rounds

- Seed, Jan 26, 2021, $0.5M — Clave Capital

## Investors

- Clave Capital — Seed